| Ticker: AVIR | 297 North Bernardo Avenue | |
| Exchange: NASDAQ-National Market | Mountain View, California 94043 | |
| Industry: Manufacturing | (415) 919-6500 |
| Type of Shares: | Common Shares | Filing Date: | 6/5/96 | |
| U.S. Shares: | 2,000,000 | Offer Date: | 11/5/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,000,000 | Offer Price: | $8.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.56 | |
| Offering Amount: | $24,000,000 | Selling: | $0.30 | |
| Expenses: | $775,000 | Reallowance: | $0.10 | |
| Shares Out After: | 12,285,990 |
| Manager | Tier | Phone |
| Robertson, Stephens & Company | Lead Manager | (415) 989-8500 |
| Bear, Stearns & Co. Inc. | Co-manager | (212) 272-2000 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 576-3423 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $1.71 | $0.19 | $0.00 | Assets: | $17.28 |
| Net Income: | -$11.40 | -$3.92 | -$3.76 | Liabilities: | $3.11 |
| EPS: | -$1.24 | -$0.41 | -$0.41 | Equity: | $14.17 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a biopharmaceutical company whose strategy is to focus on prevention of disease. The company's goal is to become a leader in the discovery, development, manufacture and marketing of live virus vaccines which are sufficiently cost effective to justify their use in immunization programs targeting the general population. Live virus vaccines, such as those for smallpox, polio measles, mumps and rubella, have had a long record of success in preventing, and in some cases eliminating, disease. The company currently is analyzing data from Phase I and Phase II clinical trials in children and adults of its live cold adapted intranasal vaccine for influenza. The company has recently in-licensed a live intranasal vaccine for Parainfluenza Virus Type 3 which has been tested by other s in Phase I/II clinical trials. The company is also developing a subunit vaccine for Epstein-Barr Virus. In addition, the company is using its proprietary "Rational Vaccine Design" technology to discover new live virus vaccines. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development including preclinical and clinical trials, capital expenditures, working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.